title: Drugs and myasthenia gravis. An update.
abstract: Myasthenia gravis is a disease of the neuromuscular junction in which normal transmission of the neuron-to-muscle impulse is impaired or prevented by acetylcholine receptor antibodies. Several classes of drugs have been associated with clinical worsening of existing myasthenia gravis, and a small subset of drugs, most notably the antirheumatic agent penicillamine, have been implicated in the pathogenesis of a variant of the disease. Recent case reports and other documented evidence link a number of specific agents with clinical worsening of myasthenia gravis.
authors.affiliation: Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy and Science, USA.
authors.forename: E T
authors.initials: ET
authors.lastname: Wittbrodt
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D006801:Humans; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000503:physiopathology; D010396:Penicillamine / Q000009:adverse effects; D009435:Synaptic Transmission / Q000187:drug effects
chemical_list: D000305:Adrenal Cortex Hormones; D018501:Antirheumatic Agents; D010396:Penicillamine